A study published Sunday by the Clalit health maintenance organization’s research institute found that the vaccine is between 91 and 99 percent effective against serious illness seven days after the second dose. But the researchers said they expected the effectiveness to rise after 14 days. (Haartz)
While the study reinforced that the vaccine is highly effective in preventing symptomatic infection a week or more after the second dose, it also showed that it was highly effective in preventing serious illness, which clinical trials were unable to prove, since there were too few cases of serious illness among the participants for the data to be statistically significant.
